Imax CEO Rich Gelfond Wades Into ‘Cliff Booth' Debate — “Frankly, I Don't Understand”

IMAX CEO Rich Gelfond questioned why some circuits will not show Netflix’s The Further Mis-Adventures of Cliff Booth during its two-week IMAX run beginning Thanksgiving weekend. He made the remarks on a call following what the article describes as terrific quarterly earnings; no results figures were provided.

Analysis

The disagreement is economic, not just a programming choice: a short, fixed theatrical window can deliver premium-screen attention for Netflix while leaving exhibitors with limited time to monetize the title. If attendance is strong, participating circuits could gain ticket and concession revenue—and strengthen their case that selective Netflix releases belong in theaters. If bookings are weak, the episode reinforces exhibitors’ concern that streaming-led releases do not support a durable theatrical window. Either outcome may matter more for future negotiating leverage than for this two-week run.

For Netflix (NFLX), the potential upside is a theatrical marketing event and audience engagement ahead of streaming availability; the offset is any concession required to secure screens and the risk that the run adds little measurable subscriber value. For IMAX (IMAX), the CEO’s public advocacy signals strategic interest, but does not establish that this title will materially affect results. The article provides no booking, attendance, revenue, or financial guidance data, so the earnings characterization alone is not a basis to extrapolate.

Near term, Thanksgiving-weekend bookings and exhibitor participation are the catalysts. Over 1–3 months, the useful read-through is whether Netflix and circuits repeat or expand the arrangement. Over 6–18 months, recurring premium releases could improve theaters’ bargaining position and make IMAX a more relevant launch partner; one title would not establish that trend. Contrarian risk: markets may overvalue the symbolic Netflix–theater relationship relative to the economics of a brief run. Weak admissions, limited screen participation, or no repeat releases would falsify the strategic-upside case.

Key Decisions for Investors

• Do not chase IMAX solely on the CEO’s comments or the article’s unquantified earnings description. Treat it as a watch item pending confirmed screen count, advance bookings, and attendance data.
• For the Thanksgiving window, monitor admissions and IMAX-specific showings against the film’s available run; strong results would support a modest read-through to exhibitor leverage, not necessarily a material estimate change for IMAX.
• Reassess NFLX only if the theatrical release produces verifiable incremental engagement—such as a measurable subscriber or retention effect—or Netflix signals repeat premium theatrical launches. A short run without evidence of those benefits weakens the marketing thesis.
• Falsifiers: poor attendance, broad circuit non-participation, or no follow-on Netflix theatrical releases. These would argue against extrapolating this event into a structural benefit for IMAX or exhibitors.